Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.
The drug demonstrated 20% average weight loss among people with obesity without Type 2 diabetes, and 17% among people with both obesity and Type 2 diabetes. Weight loss hadn't plateaued by 52 weeks, indicating patients could potentially lose more weight, Amgen said Monday.
MariTide also showed sustained reduction in hemoglobin A1c.
The trial results are informing a third phase of trials, which will last 72 weeks and will evaluate the safety, efficacy and tolerability of MariTide for overweight and obese patients with and without Type 2 diabetes.
Amgen also expects to start a Phase 3 study for atherosclerotic cardiovascular disease and heart failure, as well as a Phase 3 study for obstructive sleep apnea in 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.